Shares of SpringWorks Therapeutics (NASDAQ:SWTX) have been given a consensus rating of “Buy” by the eight analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $44.60.

A number of research firms have commented on SWTX. ValuEngine upgraded shares of SpringWorks Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, April 2nd. HC Wainwright restated a “buy” rating and set a $58.00 price objective on shares of SpringWorks Therapeutics in a research report on Tuesday, April 28th. Barclays started coverage on SpringWorks Therapeutics in a report on Tuesday, May 5th. They set an “overweight” rating and a $48.00 price target on the stock. Wedbush upped their price objective on SpringWorks Therapeutics from $45.00 to $48.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Zacks Investment Research cut SpringWorks Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, May 12th.

Several institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC grew its position in shares of SpringWorks Therapeutics by 4.4% during the first quarter. Perceptive Advisors LLC now owns 3,484,358 shares of the company’s stock valued at $94,078,000 after purchasing an additional 146,836 shares in the last quarter. BVF Inc. IL lifted its holdings in shares of SpringWorks Therapeutics by 8.3% in the 4th quarter. BVF Inc. IL now owns 3,079,155 shares of the company’s stock valued at $118,517,000 after acquiring an additional 235,010 shares during the last quarter. Driehaus Capital Management LLC lifted its holdings in shares of SpringWorks Therapeutics by 27.3% in the 1st quarter. Driehaus Capital Management LLC now owns 750,341 shares of the company’s stock valued at $20,259,000 after acquiring an additional 160,859 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of SpringWorks Therapeutics by 2.8% in the 1st quarter. BlackRock Inc. now owns 659,095 shares of the company’s stock valued at $17,795,000 after acquiring an additional 18,134 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its holdings in shares of SpringWorks Therapeutics by 0.7% in the 1st quarter. ArrowMark Colorado Holdings LLC now owns 461,071 shares of the company’s stock valued at $12,449,000 after acquiring an additional 2,993 shares during the last quarter. Hedge funds and other institutional investors own 74.24% of the company’s stock.

Shares of SWTX stock opened at $37.41 on Thursday. SpringWorks Therapeutics has a 12 month low of $17.02 and a 12 month high of $43.90. The stock has a market cap of $1.40 billion and a P/E ratio of -10.54. The company has a 50 day simple moving average of $29.42 and a two-hundred day simple moving average of $29.52.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its earnings results on Tuesday, May 12th. The company reported ($0.37) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.01. On average, sell-side analysts predict that SpringWorks Therapeutics will post -1.75 earnings per share for the current year.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.

Featured Article: Why Invest in Dividend Kings

Analyst Recommendations for SpringWorks Therapeutics (NASDAQ:SWTX)

Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.